Evidence map›Paper›PMID 31586305›Full record

ArticleClinical drug investigation2020

The Prediction Model of Warfarin Individual Maintenance Dose for Patients Undergoing Heart Valve Replacement, Based on the Back Propagation Neural Network.

Qian Li, Jing Wang, Huan Tao, Qin Zhou, Jie Chen, Bo Fu, WenZhe Qin, Dong Li, JiangLong Hou, Jin Chen and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical drug investigation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 2 countries.

Qian LiDepartment of Evidence-Based Medicine and Clinical Epidemiology, West China Hospital, Sichuan University, Guo Xue Xiang 37#, Chengdu, 610041, Sichuan, China.
Jing WangDepartment of Career Development Division, The Fourth Affiliated Hospital of Anhui Medical University, Hefei, China.
Huan TaoDepartment of Hematology, West China Hospital, Sichuan University, Chengdu, China.
Qin ZhouDepartment of Nutrition, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Jie ChenDepartment of Anesthesiology, China Mianyang Central Hospital, Mianyang, China.
Bo FuDepartment of Cardiovascular Surgery, Tianjin Central Hospital, Tianjin, China.
WenZhe QinDepartment of Social Medicine and Health Management, Shandong University, Jinan, China.
Dong LiDepartment of Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu, China.
JiangLong HouDepartment of Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu, China.
Jin ChenDepartment of Evidence-Based Medicine and Clinical Epidemiology, West China Hospital, Sichuan University, Guo Xue Xiang 37#, Chengdu, 610041, Sichuan, China. ebm_chenjin@126.com.
Wei-Hong ZhangDepartment of Research Laboratory for Human Reproduction, Faculty of Medicine and School of Public Health, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Sichuan University · CNWest China Hospital of Sichuan University · CNAnhui Medical University · CNMianyang Central Hospital · CNSecond Affiliated Hospital of Chongqing Medical University · CNShandong University · CNTianjin Central Hospital of Gynecology Obstetrics · CNUniversité Libre de Bruxelles · BE

Funding

National Natural Science Foundation 71974137National Natural Science Foundation 81641021the National Science & Technology Pillar Program during the Twelfth Five-Year Plan Period 2011BAI11B18
6 · The paper itself

Abstract

BACKGROUND AND

objectiveBecause of the narrow therapeutic window and huge inter-individual variation, the individual precision on anticoagulant therapy of warfarin is challenging. In our study, we aimed to construct a Back Propagation Neural Network (BPNN) model to predict the individual warfarin maintenance dose among Chinese patients who have undergone heart valve replacement, and validate its prediction accuracy.

methodsIn this study, we analyzed 13,639 eligible patients extracted from the Chinese Low Intensity Anticoagulant Therapy after Heart Valve Replacement database, which collected data on patients using warfarin after heart valve replacement from 15 centers all over China. Ten percent of patients who were finally enrolled in the database were used as the external validation, while the remaining were randomly divided into the training and internal validation groups at a ratio of 3:1. Input variables were selected by univariate analysis of the general linear model; 2.0, the mean value of the international normalized ratio (INR) range 1.5-2.5, was used as the mandatory variable. The BPNN model and the multiple linear regression (MLR) model were constructed by the training group and validated through comparisons of the mean absolute error (MAE), mean squared error (MSE), root mean squared error (RMSE), and ideal predicted percentage.

resultsFinally, 10 input variables were selected and a three-layer BPNN model was constructed. In the BPNN model, the value of MAE (0.688 mg/day and 0.740 mg/day in internal and external validation, respectively), MSE (0.580 mg/day and 0.599 mg/day in internal and external validation, respectively), and RMSE (0.761 mg/day and 0.774 mg/day in internal and external validation, respectively) were achieved. Ideal predicted percentages were high in both internal (63.0%) and external validation (59.7%), respectively. Compared with the MLR model, the BPNN model showed a higher ideal prediction percentage in the external validation group (59.7% vs. 56.6%), and showed the best prediction accuracy in the intermediate-dose subgroup (internal validation group: 85.2%; external validation group: 84.7%) and a high predicted percentage in the high-dose subgroup (internal validation group: 36.2%; external validation group: 39.8%), but poor performance in the low-dose subgroup (internal validation group: 0%; external validation group: 0.3%). Meanwhile, the BPNN model showed better ideal prediction percentage in the high-dose group than the MLR model (internal validation: 36.2% vs. 31.6%; external validation: 42.8% vs. 37.8%).

conclusionThe BPNN model shows promise for predicting the warfarin maintenance dose after heart valve replacement.

Indexed as

Heart Valve Prosthesis ImplantationAdultAlgorithmsAnticoagulantsAsian PeopleChinaFemaleHeart ValvesHumansInternational Normalized RatioMaleMiddle AgedWarfarinAnticoagulantsWarfarin

Identifiers

PMID31586305
OpenAlexW2978310679

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.